Lehane D E, Hurd E, Lane M
Cancer Res. 1975 Oct;35(10):2724-8.
Bleomycin was administered to six patients with advanced cancer. Multiple parameters of both antibody- and cell-mediated immunity were followed serially to characterize the effects of bleomycin on immunocompetence in humans. Antibody-mediated immunity, including primary vaccination with keyhole limpet hemocyanin, was not depressed. While there was no significant suppression of cell-mediated immunity, phytohemagglutinin-stimulated lymphocyte blastogenesis was reduced after treatment with bleomycin. The in vitro effects of bleomycin on lymphocyte stimulation were studied, and while thymidine incorporation was significantly inhibited by bleomycin, leucine incorporation was not reduced even at high concentrations of bleomycin. We have concluded that bleomycin does not suppress immunocompetence in man.
对6例晚期癌症患者给予博来霉素治疗。连续监测抗体介导免疫和细胞介导免疫的多个参数，以表征博来霉素对人体免疫能力的影响。抗体介导的免疫，包括用钥孔戚血蓝蛋白进行初次接种，未受到抑制。虽然细胞介导免疫没有受到显著抑制，但博来霉素治疗后植物血凝素刺激的淋巴细胞增殖受到了抑制。研究了博来霉素对淋巴细胞刺激的体外作用，虽然博来霉素显著抑制了胸腺嘧啶核苷掺入，但即使在高浓度博来霉素作用下，亮氨酸掺入也未减少。我们得出结论，博来霉素不会抑制人体的免疫能力。
